keyword
MENU ▼
Read by QxMD icon Read
search

Vinflunine

keyword
https://www.readbyqxmd.com/read/28633191/-urothelial-cancer-update-on-systemic-treatment-options
#1
Günter Niegisch
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern treatment of patients with muscle-invasive urothelial bladder cancer. All patients who are suitable for cisplatin-based chemotherapy should be involved in a corresponding concept.Cisplatin-based combinations are standard regimens in the perioperative and palliative systemic treatment of urothelial cancer. Carboplatin is only an inferior substitute for "unfit" patients in the palliative treatment situation...
June 20, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28591872/-the-role-of-immunooncology-in-the-treatment-of-urothelial-cancer
#2
Margitta Retz, Robert Tauber, Thomas Horn
Data published in November 2016 showed a significant survival benefit for the PD-1 antibody Pembrolizumab in the second-line treatment of metastatic urothelial cancer in comparison to standard chemotherapy. Other PD-1/PD-L1 antibodies are being tested in advanced clinical trials. This class of substances will become standard of care from the time of their approval which is expected for 2017 and will replace vinflunine, which is currently recommended in the German guideline. PD-1/PD-L1 directed substances are also being tested as a first line treatment of metastatic urothelial carcinoma...
June 7, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28588741/erratum-vinflunine-treatment-in-patients-with-metastatic-urothelial-cancer-a-nordic-retrospective-multicenter-analysis
#3
Karin Holmsten, Line Dohn, Niels Viggo Jensen, Carl-Henrik Shah, Fredrik Jäderling, Helle Pappot, Anders Ullén
[This corrects the article DOI: 10.3892/ol.2016.4775.].
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28466878/urological-cancer-vinflunine-is-an-effective-maintenance-therapy
#4
Peter Sidaway
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28427506/recent-advances-in-genitourinary-tumors-a-review-focused-on-biology-and-systemic-treatment
#5
REVIEW
Aránzazu González Del Alba, José Ángel Arranz, Javier Puente, María José Méndez-Vidal, Enrique Gallardo, Enrique Grande, Begoña Pérez-Valderrama, Enrique González-Billalabeitia, Martín Lázaro-Quintela, Álvaro Pinto, Nuria Lainez, Josep M Piulats, Emilio Esteban, José Pablo Maroto Rey, Jorge A García, Cristina Suárez
Updated information published up to 2016 regarding major advances in renal cancer, bladder cancer, and prostate cancer is here presented. Based on an ever better understanding of the genetic and molecular alterations that govern the initial pathogenic mechanisms of tumor oncogenesis, an improvement in the characterization and treatment of urologic tumors has been achieved in the past year. According to the Cancer Genome Atlas (ATLAS) project, alterations in the MET pathway are characteristics of type 1 papillary renal cell carcinomas, and activation of NRF2-ARE pathway is associated with the biologically distinct type 2...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28419193/a-randomized-phase-ii-iii-study-of-cabazitaxel-versus-vinflunine-in-metastatic-or-locally-advanced-transitional-cell-carcinoma-of-the-urothelium-secavin
#6
J Bellmunt, J M Kerst, F Vázquez, R Morales-Barrera, E Grande, A Medina, Mªb González Graguera, G Rubio, U Anido, O Fernández Calvo, E González-Billalabeitia, Ajm Van den Eertwegh, E Pujol, J L Perez-Gracia, J L González Larriba, R Collado, M Los, S Maciá, R De Wit
BACKGROUND: Despite the advent of immunotherapy in urothelial cancer, there is still a need to find effective cytotoxic agents beyond first and second line. Vinflunine is the only treatment approved in this setting by the European Medicines Agency (EMA) and taxanes are also widely used in second line. Cabazitaxel is a taxane with activity in docetaxel-refractory cancers. A randomized study was conducted to compare its efficacy vs vinflunine. PATIENTS AND METHODS: This is a multicenter, randomized, open-label, phase II/III study, following a Simon's optimal method with stopping rules based on an interim futility analysis and a formal efficacy analysis at the end of the phase II...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28389316/maintenance-therapy-with-vinflunine-plus-best-supportive-care-versus-best-supportive-care-alone-in-patients-with-advanced-urothelial-carcinoma-with-a-response-after-first-line-chemotherapy-maja-sogug-2011-02-a-multicentre-randomised-controlled-open-label-phase
#7
Jesus García-Donas, Albert Font, Begoña Pérez-Valderrama, José Antonio Virizuela, Miquel Ángel Climent, Susana Hernando-Polo, José Ángel Arranz, Maria Del Mar Llorente, Nuria Lainez, José Carlos Villa-Guzmán, Begoña Mellado, Aránzazu González Del Alba, Daniel Castellano, Enrique Gallardo, Urbano Anido, Xavier García Del Muro, Montserrat Domènech, Javier Puente, Rafael Morales-Barrera, Jose Luis Pérez-Gracia, Joaquim Bellmunt
BACKGROUND: Maintenance therapy improves outcomes in various tumour types, but cumulative toxic effects limit the choice of drugs. We investigated whether maintenance therapy with vinflunine would delay disease progression in patients with advanced urothelial carcinoma who had achieved disease control with first-line chemotherapy. METHODS: We did a randomised, controlled, open-label, phase 2 trial in 21 Spanish hospitals. Eligible patients had locally advanced, surgically unresectable, or metastatic transitional-cell carcinoma of the urothelial tract, adequate organ function, and disease control after four to six cycles of cisplatin and gemcitabine (carboplatin allowed after cycle four)...
April 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28212060/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma
#8
RANDOMIZED CONTROLLED TRIAL
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri, Andrea Necchi, Winald Gerritsen, Howard Gurney, David I Quinn, Stéphane Culine, Cora N Sternberg, Yabing Mai, Christian H Poehlein, Rodolfo F Perini, Dean F Bajorin
BACKGROUND: Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options. METHODS: In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy to receive pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1 [PD-1]) at a dose of 200 mg every 3 weeks or the investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine...
March 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28098864/victor-vinflunine-in-advanced-metastatic-transitional-cell-carcinoma-of-the-urothelium-a-retrospective-analysis-of-the-use-of-vinflunine-in-multi-centre-real-life-setting-as-second-line-chemotherapy-through-free-of-charge-programme-for-patients-in-the-uk-and
#9
MULTICENTER STUDY
Syed A Hussain, Jawaher Ansari, Robert Huddart, Derek G Power, Jeanette Lyons, James Wylie, Maria Vilarino-Varlela, Nils O Elander, Rhona McMenemin, Lisa M Pickering, Guy Faust, Seema Chauhan, Richard J Jackson
There is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have failed a platinum-based regimen, and is standard of care in Europe but is not routinely available in the UK. Data were collected retrospectively on patients who received vinfluine as a second-line treatment. The aims were to document the toxicity and efficacy in a real life setting. Data were collected on 49 patients from 9 sites across the UK and Ireland [median age, 64 (IQR, 57-70) years, 33 males]...
March 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28042310/vinflunine-in-the-treatment-of-advanced-urothelial-cancer-clinical-evidence-and-experience
#10
REVIEW
Holger Gerullis, Friedhelm Wawroschek, Claus-Henning Köhne, Thorsten Holger Ecke
Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.
January 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27900539/seom-clinical-guideline-for-treatment-of-muscle-invasive-and-metastatic-urothelial-bladder-cancer-2016
#11
M Lázaro, E Gallardo, M Doménech, Á Pinto, A González Del Alba, J Puente, O Fernández, A Font, N Lainez, S Vázquez
The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27846935/-ccafu-french-national-guidelines-2016-2018-on-bladder-cancer
#12
REVIEW
M Rouprêt, Y Neuzillet, A Masson-Lecomte, P Colin, E Compérat, F Dubosq, N Houédé, S Larré, G Pignot, P Puech, M Roumiguié, E Xylinas, A Méjean
OBJECTIVE: The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumour...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27812861/metastatic-bladder-cancer-second-line-treatment-and-recommendations-of-the-genitourinary-tumor-division-of-the-galician-oncologic-society-sog-gu
#13
REVIEW
Jorge García, Lucia Santomé, Urbano Anido, Ovidio Fernández-Calvo, Javier Afonso-Afonso, Martín Lázaro, Ana Medina, Sergio Vázquez Estévez
Once metastatic bladder cancer has progressed to first-line treatment, the number of therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is the only one shown to increase overall survival in a phase III trial. In addition to its efficacy, VFL is safe in special population groups. Despite this, the prognosis for these patients remains poor, and more effective therapies need to be developed. Agents acting on new therapeutic targets as well as biomarkers to aid matching patients to specific treatments are currently under evaluation...
December 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/27771969/vinflunine-for-the-treatment-of-non-small-cell-lung-cancer
#14
REVIEW
C Genova, A Alama, S Coco, E Rijavec, M G Dal Bello, I Vanni, F Biello, G Barletta, G Rossi, F Grossi
Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the microtubule dynamics during cell cycle; this agent is currently available for previously treated advanced transitional cell carcinoma in Europe. The aim of this invited review is to evaluate the potential role of vinflunine for the treatment of non-small cell lung cancer (NSCLC). Areas covered: The potential role of vinflunine in NSCLC is discussed on the basis of the available data, including full papers and meeting abstracts. Relevant preclinical studies describing the pharmacological properties of vinflunine are also included...
December 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27664126/epicure-a-european-epidemiological-study-of-patients-with-an-advanced-or-metastatic-urothelial-carcinoma-uc-having-progressed-to-a-platinum-based-chemotherapy
#15
N Houédé, G Locker, C Lucas, H Soto Parra, U Basso, D Spaeth, R Tambaro, L Basterretxea, F Morelli, C Theodore, L Lusuardi, N Lainez, A Guillot, G Tonini, J Bielle, X Garcia Del Muro
BACKGROUND: Platinum-based systemic chemotherapy is considered the backbone for management of advanced urothelial carcinomas. However there is a lack of real world data on the use of such chemotherapy regimens, on patient profiles and on management after treatment failure. METHODS: Fifty-one randomly selected physicians from 4 European countries registered 218 consecutive patients in progression or relapse following a first platinum-based chemotherapy. Patient characteristics, tumor history and treatment regimens, as well as the considerations of physicians on the management of urothelial carcinoma were recorded...
September 23, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27519420/metabolic-complete-response-with-vinflunine-as-second-line-therapy-in-a-kidney-transplanted-patient-with-advanced-urothelial-carcinoma-a-case-report
#16
Paola Bordi, Marcello Tiseo, Giorgio Baldari, Sebastiano Buti
BACKGROUND: Patients undergone kidney transplantation present higher risk of Urothelial Carcinoma (UC) development and represent a subgroup of special interest. To date, vinflunine is the only drug approved in Europe for the treatment of advanced UC after failure of platinum-based chemotherapy. However, to our knowledge, no data on the concomitant administration of vinflunine and immunosuppressive agents are available. CASE PRESENTATION: The patient, a 45 years old Caucasian male, presented poorly differentiated UC of the bladder recurred after initial cystectomy with abdominal lymphadenopathies evidenced by FDG-PET/CT...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27484180/vinflunine-for-the-treatment-of-breast-cancer
#17
REVIEW
Carole Gourmelon, Héloïse Bourien, Paule Augereau, Anne Patsouris, Jean-Sébastien Frenel, Mario Campone
INTRODUCTION: Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. Its arrival has been eagerly awaited for treatment of solid tumors, and in particular, for metastatic breast cancer. AREAS COVERED: The pharmacological features of vinflunine are described...
September 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27446429/vinflunine-treatment-in-patients-with-metastatic-urothelial-cancer-a-nordic-retrospective-multicenter-analysis
#18
Karin Holmsten, Line Dohn, Niels Viggo Jensen, Carl-Henrik Shah, Fredrik Jäderling, Helle Pappot, Anders Ullén
In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluating treatment patterns, response, survival parameters and side-effects. Data were collected retrospectively from the first 100 mUC patients treated with vinflunine at three Nordic cancer centers associated with the Nordic Urothelial Cancer Oncology Group...
August 2016: Oncology Letters
https://www.readbyqxmd.com/read/27353965/re-vinflunine-gemcitabine-versus-vinflunine-carboplatin-as-first-line-chemotherapy-in-cisplatin-unfit-patients-with-advanced-urothelial-carcinoma-results-of-an-international-randomized-phase-ii-trial-jasint1
#19
https://www.readbyqxmd.com/read/27306417/systemic-therapy-in-muscle-invasive-and-metastatic-bladder-cancer-current-trends-and-future-promises
#20
REVIEW
Jeanny B Aragon-Ching, Donald L Trump
Bladder urothelial cancers remain an important urologic cancer with limited treatment options in the locally advanced and metastatic setting. While neoadjuvant chemotherapy for locally advanced muscle-invasive cancers has shown overall survival benefit, clinical uptake in practice have lagged behind. Controversies surrounding adjuvant chemotherapy use are also ongoing. Systemic therapies for metastatic bladder cancer have largely used platinum-based therapies without effective standard second-line therapy options for those who fail, although vinflunine is approved in Europe as a second-line therapy based on a Phase III trial, and most recently, atezolizumab, a checkpoint inhibitor, was approved by the US FDA...
September 2016: Future Oncology
keyword
keyword
31934
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"